Literature DB >> 24829857

Maintaining clarity: Review of maintenance therapy in non-small cell lung cancer.

Kristen R Dearing1, Ashish Sangal1, Glen J Weiss1.   

Abstract

The purpose of this article is to review the role of maintenance therapy in the treatment of advanced non-small cell lung cancer (NSCLC). A brief overview about induction chemotherapy and its primary function in NSCLC is provided to address the basis of maintenance therapies foundation. The development of how maintenance therapy is utilized in this population is discussed and current guidelines for maintenance therapy are reviewed. Benefits and potential pitfalls of maintenance therapy are addressed, allowing a comprehensive review of the achieved clinical benefit that maintenance therapy may or may not have on NSCLC patient population. A review of current literature was conducted and a table is provided comparing the results of various maintenance therapy clinical trials. The table includes geographical location of each study, the number of patients enrolled, progression free survival and overall survival statistics, post-treatment regimens and if molecular testing was conducted. The role of molecular testing in relation to therapeutic treatment options for advanced NSCLC patients is discussed. A treatment algorithm clearly depicts first line and second line treatment for management of NSCLC and includes molecular testing, maintenance therapy and the role clinical trials have in treatment of NSCLC. This treatment algorithm has been specifically tailored and developed to assist clinicians in the management of advanced NSCLC.

Entities:  

Keywords:  Clinical trials; Maintenance therapy; Molecular aberrations; Non-small cell lung cancer; Overall survival; Progression-free survival

Year:  2014        PMID: 24829857      PMCID: PMC4014782          DOI: 10.5306/wjco.v5.i2.103

Source DB:  PubMed          Journal:  World J Clin Oncol        ISSN: 2218-4333


  30 in total

1.  Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy.

Authors:  David E Gerber; Drew W Rasco; Phat Le; Jingsheng Yan; Jonathan E Dowell; Yang Xie
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

Review 2.  Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.

Authors:  Yu Yang Soon; Martin R Stockler; Lisa M Askie; Michael J Boyer
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

3.  Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.

Authors:  Virginie Westeel; Elisabeth Quoix; Denis Moro-Sibilot; Mariette Mercier; Jean-Luc Breton; Didier Debieuvre; Philippe Richard; Mary-Anne Haller; Bernard Milleron; Dominique Herman; Marie-Claude Level; François-Xavier Lebas; Marc Puyraveau; Alain Depierre
Journal:  J Natl Cancer Inst       Date:  2005-04-06       Impact factor: 13.506

4.  Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.

Authors:  Thomas Brodowicz; Maciej Krzakowski; Matjaz Zwitter; Valentina Tzekova; Rodryg Ramlau; Nicolae Ghilezan; Tudor Ciuleanu; Branka Cucevic; Kalman Gyurkovits; Ernst Ulsperger; Jacek Jassem; Mislav Grgic; Pinar Saip; Maria Szilasi; Christoph Wiltschke; Maria Wagnerova; Natalya Oskina; Victoria Soldatenkova; Christoph Zielinski; Miklos Wenczl
Journal:  Lung Cancer       Date:  2006-03-29       Impact factor: 5.705

5.  PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

Authors:  Luis G Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujol; Paolo Bidoli; Olivier Molinier; Tarini Prasad Sahoo; Eckart Laack; Martin Reck; Jesús Corral; Symantha Melemed; William John; Nadia Chouaki; Annamaria H Zimmermann; Carla Visseren-Grul; Cesare Gridelli
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

6.  Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).

Authors:  Fabrice Barlesi; Arnaud Scherpereel; Achim Rittmeyer; Antonio Pazzola; Neus Ferrer Tur; Joo-Hang Kim; Myung-Ju Ahn; Joachim G J V Aerts; Vera Gorbunova; Anders Vikström; Elaine K Wong; Pablo Perez-Moreno; Lada Mitchell; Harry J M Groen
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

Review 7.  Adherence to oral antineoplastic agents by cancer patients: definition and literature review.

Authors:  F Bassan; F Peter; B Houbre; M J Brennstuhl; M Costantini; E Speyer; C Tarquinio
Journal:  Eur J Cancer Care (Engl)       Date:  2013-09-15       Impact factor: 2.520

8.  Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.

Authors:  K N Syrigos; J Vansteenkiste; P Parikh; J von Pawel; C Manegold; R G Martins; L Simms; K P Sugarman; C Visseren-Grul; G V Scagliotti
Journal:  Ann Oncol       Date:  2009-10-14       Impact factor: 32.976

9.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

Review 10.  Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis.

Authors:  João Paulo da Silveira Nogueira Lima; Lucas Vieira dos Santos; Emma Chen Sasse; Andre Deeke Sasse
Journal:  Eur J Cancer       Date:  2008-12-26       Impact factor: 9.162

View more
  8 in total

Review 1.  Intracellular and intercellular signaling networks in cancer initiation, development and precision anti-cancer therapy: RAS acts as contextual signaling hub.

Authors:  Peter Csermely; Tamás Korcsmáros; Ruth Nussinov
Journal:  Semin Cell Dev Biol       Date:  2016-07-06       Impact factor: 7.727

2.  The unmet supportive care needs-what advanced lung cancer patients' caregivers need and related factors.

Authors:  Shu-Ching Chen; Shiuan-Chen Chiou; Chong-Jen Yu; Yun-Hsiang Lee; Wei-Yu Liao; Pei-Yin Hsieh; Sin-Yuan Jhang; Yeur-Hur Lai
Journal:  Support Care Cancer       Date:  2016-02-13       Impact factor: 3.603

Review 3.  The war on cancer: lessons from the war on terror.

Authors:  Sui Huang
Journal:  Front Oncol       Date:  2014-10-20       Impact factor: 6.244

4.  The action mechanism of lncRNA-HOTAIR on the drug resistance of non-small cell lung cancer by regulating Wnt signaling pathway.

Authors:  Feng Guo; Zhili Cao; Huiqin Guo; Shanqing Li
Journal:  Exp Ther Med       Date:  2018-04-11       Impact factor: 2.447

5.  Prospective Randomized Phase II Parallel Study of Vinorelbine Maintenance Therapy versus Best Supportive Care in Advanced Non-Small Cell Lung Cancer.

Authors:  Adnan Khosravi; Zahra Esfahani-Monfared; Sharareh Seifi; Kian Khodadad
Journal:  Tanaffos       Date:  2017

6.  High EMT Signature Score of Invasive Non-Small Cell Lung Cancer (NSCLC) Cells Correlates with NFκB Driven Colony-Stimulating Factor 2 (CSF2/GM-CSF) Secretion by Neighboring Stromal Fibroblasts.

Authors:  Albin Rudisch; Matthew Richard Dewhurst; Luminita Gabriela Horga; Nina Kramer; Nathalie Harrer; Meng Dong; Heiko van der Kuip; Andreas Wernitznig; Andreas Bernthaler; Helmut Dolznig; Wolfgang Sommergruber
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

7.  Percutaneous CT-guided microwave ablation as maintenance after first-line treatment for patients with advanced NSCLC.

Authors:  Xiang Ni; Jun-Qing Han; Xin Ye; Zhi-Gang Wei
Journal:  Onco Targets Ther       Date:  2015-11-03       Impact factor: 4.147

Review 8.  Role of Topotecan in Non-Small Cell Lung Cancer: A Review of Literature.

Authors:  Adarsh Vennepureddy; Jean-Paul Atallah; Terenig Terjanian
Journal:  World J Oncol       Date:  2015-10-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.